Calcilytic NPS 2143 Reduces Amyloid Secretion and Increases sAβPPα Release from PSEN1 Mutant iPSC-Derived Neurons

INTRODUCTION

Alzheimer’s disease (AD) represents the most common cause of dementia with 50 million patients currently around the world. The lack of a cure and the failure of clinical trials over the years clearly demonstrate that the pathomechanism of AD is not yet completely understood. Moreover, evidence strongly indicates that AD is a multifactorial disease, with several aberrant processes contributing to it [1]. Amyloid accumulation and tau hyperphosphorylation are responsible for extracellular amyloid plaques and intracellular neurofibrillary tangles, respectively, both of which constitute the biochemical signatures of the disease [2–4]. Furthermore, oxidative stress, mitochondrial dysfunction, synaptic failure, and neuroinflammation widely characterize AD [5–8]. In addition to the multiplicity of pathological mechanisms concurring in AD, a main difficulty in studying the disease is represented by the limited access to human brain and the analyses of postmortem cortex samples which give information on the very late stage of the disease, making the understanding of the early pathogenic processes more challenging. Another problematic aspect is the limited relevance of in vitro and in vivo systems used to model AD. Indeed, use of transgenic models overexpressing the clinical mutations in the amyloid-β protein precursor (AβPP) or in the γ-secretase subunits PSEN1 and PSEN2, responsible for the familial form of AD (fAD), often lead to an overestimation of the efficacy of candidate drugs. This was the case for a group of nonsteroidal anti-inflammatory drugs, including flurbiprofen and indomethacin, which act as γ-secretase modulators. Such compounds were highly efficacious in lowering the production of Aβ₄₂ in transgenic immortalized cell lines [9], but failed to exert any positive effect in human-derived neurons [10] and in clinical trials [11]. Moreover, transgenic animal models were ineffective to fully reproduce the pathological aspects of the human disease [12]. In this context, induced pluripotent stem cell (iPSC) technology provided a novel tool to overcome the limitations of transgenic systems and to alternatively approach the study of AD. In the last years, several groups, including ours, generated human iPSC-derived neurons from individuals with familial and sporadic AD. Compared to healthy iPSC neurons, neuronal lines generated from AD subjects presented overall augmented amyloid levels and increased Aβ₄₂/Aβ₄₀ ratios [13–16], which strongly resembles what happens in the brain of the patients. Interestingly, a study conducted on iPSC-three-dimensional (3D) neurons derived from AD subjects revealed a dysfunction of a number of proteins involved in axon growth, mitochondrial function, and oxidative stress, which were comparable to the alterations found in postmortem AD brain tissues [17]. In addition, a recent report established that the Aβ₃₈/Aβ₄₀ ratio measured in cerebrospinal fluid (CSF) from a patient with the AβPP V717I mutation was similar to the ratio observed in the cell culture medium of iPSC-neurons derived from the same subject, whereas the Aβ₄₂/Aβ₄₀ ratio of the patient’s CSF was lower than the ratio in the media from iPSC-neurons, which is consistent with deposition of amyloidogenic Aβ₄₂ into Aβ plaques [18]. Such remarkable results provide the first correlation between CSF profiles from patients and their own Aβ secretome in the differentiated neuronal cultures, thus substantiating patient-derived cells as a reliable system to model the pathomechanisms of the disease [19, 20]. In addition to amyloid defects, tau hyperphosphorylation and increased GSK3β activity were also recapitulated in neurons differentiated from familial and sporadic AD patients [16, 21–23]. Therefore, iPSC-based systems promise to provide more suitable platforms for validation of candidate drugs and for identification of novel therapeutic targets.

In this regard, reports indicated the calcium sensing receptor (CaSR) as a potential key player in AD [24–26]. CaSR is a G-protein coupled receptor (GPCR) mainly expressed in the parathyroid glands where it exerts its primary role in sensing extracellular Ca²⁺ levels and in regulating parathyroid hormone secretion accordingly [27]. The receptor’s activity can be stimulated or inhibited by calcimimetics and calcilytics, which are positive and negative allosteric modulators, respectively [28]. In addition to Ca²⁺ ions, the receptor responds to several other agonists and plays different functions, other than maintaining Ca²⁺ homeostasis, in a tissue-dependent manner [29]. In the nervous system, CaSR is involved in physiological processes such as neurodevelopment [30] and synaptic transmission [31]. Moreover, a role for the receptor in mediating neuronal death upon hypoxia or ischemia [32] and in regulating amyloid production and secretion [33, 34] has been described. Relevant to AD, recent studies showed the capacity of synthetic amyloid-β (Aβ) to bind and activate the CaSR of non-tumorigenic cortical adult human astrocytes (NAHAs) [34, 35]. In particular, NAHAs increased the secreted amount of endogenous amyloid and hyperphosphorylated tau when exposed to synthetic Aβ. Noteworthy, co-treatment with calcilytic NPS 2143 fully inhibited such effects on amyloid and tau [34, 36], while it increased the release of soluble sAβPPα [37]. Based on these results, the authors hypothesized that Aβ/CaSR-activated signaling promoted de novo production and release of amyloid together with over-release of tau, thus feeding a vicious cycle. Accordingly, negative modulation of the receptor with calcilytic efficiently counteracted the Aβ/CaSR-mediated noxious effects by favoring the non-amyloidogenic pathway of AβPP and blocking the vicious cycle [37]. Consequently, inhibition of CaSR was proposed as a relevant approach for AD and the calcilytic NPS 2143 as potential therapeutic.

Considering this promising evidence, we set up a study aimed to assess the effect of NPS 2143 in iPSC-neurons differentiated from a patient with familial AD carrying a genetic mutation in PSEN1. Indeed, we previously characterized iPSC-neurons derived from healthy individuals and from patients with sporadic and familial AD [16]. We found that AD neurons secreted higher levels of amyloid compared to healthy cultures, whereas a significantly higher Aβ₄₂/Aβ₄₀ ratio with respect to control cells was detected only in fAD neurons [16].

To validate our in vitro system as a platform for the screening of potential anti-AD compounds, in the present study we first characterized the modulation of AβPP processing and amyloid secretion in control and fAD neurons, upon exposure to the potent γ-secretase inhibitor, DAPT. Next, we assessed CaSR expression in healthy and fAD differentiated neuronal cells as no evidence exists in this regard. Finally, we evaluated the impact of calcilytic NPS 2143 on amyloid secretion and on location at the plasma membrane of CaSR and proteins relevant for AβPP processing in human iPSC-derived neurons.

MATERIALS AND METHODS

The chemicals used were purchased from Sigma-Aldrich (St. Louis, MO, USA), and the cell culture reagents and culture plates were purchased from Thermo Fisher Scientific (Waltham, MA, USA), unless specified otherwise.

RESULTS

Characterization of iPSC-derived neurons

Human iPSC lines, reprogrammed from a fAD patient and from non-AD control individuals, were previously characterized by our group and successfully converted into neural progenitor cells [16, 38]. Here, we let control and fAD NPCs to terminally differentiate toward neuronal cells for 6 weeks. By immunostainings, we confirmed the differentiation of NPCs, stained with the specific markers PAX6 and Nestin, into neurons expressing MAP2 and tau (Fig. 1A). Moreover, Ca²⁺ imaging analyses conducted on 4-week differentiated control and fAD cultures revealed that cells positively respond to stimulation with high KCl, GABA, AMPA, and kainic acid, demonstrating that neurons express functional voltage gated ion channels, GABA receptors, and ionotropic glutamate receptors, already at this stage of differentiation (representative traces from control and fAD cells are shown in Fig. 1B). In accordance with our previous findings [16], no evident differences between neuronal cultures, differentiated from control and fAD iPSC were observed, which prompted us to use these cell lines for further experiments.

Fig.1

Neuronal differentiation of Ctrl and fAD iPSC-derived neural progenitors, NPCs. A) Representative immunocytochemical analyses showing the differentiation of NPCs, expressing the specific markers PAX6 in nuclei (green) and NESTIN cytoplasmic intermediate filaments (red), in 6-weeks old neurons, stained with MAP2 (red) and TAU (green); for color images, see the online version. Scale bar 20 μM. B) Calcium intracellular influx recorded from fura-2 loaded 4-weeks old neurons (Ctrl-1 and fAD-1 cell lines) in response to 60 mM KCl, 100 μM GABA in physiological extracellular chloride (GABA), 100 μM GABA in 7.5 mM chloride (GABA in low Cl-), 100 μM AMPA and 100 μM Kainic acid, demonstrating functional expression of voltage gated ion channels, GABA receptors and ionotropic glutamate receptors.

Modulation of AβPP processing and amyloid secretion by γ-secretase inhibition in iPSC-derived neuronal cells

In order to use patient-derived neurons as a cellular system suitable for modeling AD-related physiological changes, we first assessed the effects of the potent γ-secretase inhibitor DAPT on AβPP physiological processing and Aβ secretion. In line with our previous report in which multiple control, sporadic, and familial AD cell lines were analyzed [16], ELISA of conditioned media confirmed that PSEN1 mutant neurons presented a higher Aβ₄₂/Aβ₄₀ ratio compared to control cells in this study (Fig. 2B, Vehicle condition). Data from each Aβ species showed that this ratio change was primarily due to an approximately 2-fold increase in the production of Aβ₄₂ in fAD neurons compared to control cell lines (Fig. 2A, Vehicle condition). Importantly, 48 h treatment with DAPT (1 μM) drastically reduced the secretion of Aβ₄₀ and Aβ₄₂ from both control and fAD neurons (Fig. 2A, DAPT condition). Nevertheless, the ratio between Aβ₄₂ and Aβ₄₀ in fAD cells treated with DAPT remained higher than the ratio observed in control cells (Fig. 2B, DAPT condition). Consistent with inhibition of γ-secretase activity, WB analyses of lysates from healthy and PSEN1 mutant neurons demonstrated that DAPT treatment led to a strong accumulation of AβPP-C terminal fragment (AβPP-CTF), which constitutes the substrate of γ-secretase [39] (Fig. 2C). These observations demonstrated that AβPP and amyloid processing of control and patient-derived neurons efficiently respond to pharmacological modulation with γ-secretase inhibitor, thus allowing the use of this cellular model to explore the potential of calcilytic in these processes.

Fig.2

Pharmacological modulation of amyloid secretion and AβPP processing by DAPT treatment. A) ELISA analyses of Aβ₄₀ and Aβ₄₂ endogenously secreted into conditioned media from controls (Ctrl-1 and Ctrl-2) and fAD cell lines treated with vehicle (0.1% DMSO) or with 1 μM DAPT for 48 h. Data normalized to total mg of protein. B) Ratio between Aβ₄₂ and Aβ₄₀ secreted from controls (Ctrl-1 and Ctrl-2) and fAD cell lines±treatment with 1 μM DAPT for 48 h. C) Representative western blot analysis of total lysates showing the accumulation of AβPP-CTF upon treatment with 1 μM DAPT for 48 h; In A and B, two-tailed t-tests were performed when comparing different conditions (vehicle and DAPT) within the same cell line, while one-way ANOVA performed with Tukey’s multiple comparisons test was applied to find differences between the cell lines. *p < 0.05; Error bars = SEM; ELISA and WB measurements were performed at least as biological triplicates.

CaSR expression in human iPSC-derived neurons

Although there is evidence showing that CaSR is expressed in several regions of human brain [40] and in human astrocytes [41, 42], no data is available in human iPSC-derived neuronal cultures. By ICC, we showed that CaSR is expressed in 6-week-old MAP2 positive neurons differentiated from control and fAD human NPCs (Fig. 3A). Furthermore, WB analyses confirmed that control and fAD cells present CaSR-specific proteins, representing both the monomeric form at ∼120–130 kDa and the dimeric form at ∼250–260 kDa (Fig. 3B). No evident differences were observed between healthy and PSEN1 mutant cells regarding the expression of the receptor. A lower level of receptor protein expression and only the monomeric form of CaSR was detected in control human hippocampal brain postmortem sample (Fig. 3B). Moreover, as positive controls, human neuroblastoma SH-SY5Y, transiently transfected with the HA-tagged human-CaSR, and human kidney lysate showed similar pattern of CaSR expression (Supplementary Figure 1). In conclusion, we detected the expression of CaSR on both control and fAD iPSC-derived human neurons for the first time.

Fig.3

CaSR expression in differentiated neuronal cultures. A) Immunocytochemical analysis showing the CaSR expression (in red) in neurons, co-stained with MAP2 (in blue); for color images see the online version. B) Representative western blot of control and fAD lysates demonstrating the receptor positive bands at ∼130 kDa and ∼260 kDa which should represent the monomeric and dimeric forms of CaSR. Human control adult hippocampal brain lysate has been loaded as positive control of CaSR expression in human brain.

Reduced amyloid secretion and increased sAβPPα release in the media of fAD neural cells treated with calcilytic NPS 2143

Research reported that calcilytic promoted the sAβPPα release while it inhibited Aβ₄₂ accumulation and secretion in human astrocytes treated with exogenous Aβ [34, 37]. To evaluate the effect of calcilytic in iPSC-derived neurons, we treated 6-week-old control and fAD cells with NPS 2143 for 48 h. ELISA analyses of conditioned media revealed that treatment with calcilytic had no significant effect on Aβ secretion in control cell lines (Fig. 4A). On the contrary, NPS 2143 reduced the levels of Aβ₄₀ and Aβ₄₂ in the conditioned media of fAD cells about 25% compared to the vehicle-treated cells (Fig. 4A). Moreover, as calcilytic caused a similar reduction of both amyloid species in fAD neurons, the resulting ratio between the Aβ₄₂ and Aβ₄₀ in PSEN1 mutant cells treated with NPS 2143 was not changed compared to the treatment with vehicle, remaining significantly higher than the ratio showed by the control cell lines (Fig. 4B). However, the levels of AβPP full-length and AβPP-CTF were not modified by calcilytic, which ruled out the possibility that NPS 2143 could act in a γ-secretase inhibitor fashion (Supplementary Figure 2). In addition, we assessed the sAβPPα release extracellularly. Interestingly, WB analyses of conditioned media demonstrated that fAD neurons secreted significantly lower amount of sAβPPα compared to the control cell lines (Fig. 5A). Interestingly, calcilytic strongly increased the release of sAβPPα from fAD cells, whereas no evident effect was observed in control cells (Fig. 5B). All together such results suggest that NPS 2143 favored the AβPP non-amyloidogenic α-pathway, while it decreased the amyloidogenic β-processing only in cells with PSEN1 mutation.

Fig.4

Modulation of amyloid secretion by NPS 2143 treatment. A) ELISA analyses of Aβ₄₀ and Aβ₄₂ endogenously secreted into conditioned media from controls (Ctrl-1 and Ctrl-2) and fAD cell lines treated with vehicle (0.1% DMSO) or with 1 μM NPS 2143 for 48 h. Vehicle treated samples were considered as 100%, while NPS 2143 treated samples were presented in the percentage of the vehicle. Two-tailed t-tests were performed. *p < 0.05; Error bars = SEM. B) Ratio between Aβ₄₂ and Aβ₄₀ endogenously secreted from controls and fAD cell lines upon the treatment with 1 μM NPS 2143 for 48 h. One-way ANOVA performed with Tukey’s multiple comparisons test was applied to find differences between the cell lines. *p < 0.05; Error bars = SEM.

Fig.5

Modulation of sAβPPα secretion by NPS 2143 treatment. A) sAβPPα secreted by control (Ctrl-1 and Ctrl-2) and fAD neuronal cultures into conditioned medium detected by immunoblot with 6E10 antibody. Densitometric values were normalized to total mg of protein. B) sAβPPα secreted by control (Ctrl-1 and Ctrl-2) and fAD neuronal cultures treated with vehicle (0.1% DMSO) or with 1 μM NPS 2143 for 48 h. Vehicle treated samples were considered as 100%, while NPS 2143 treated samples were presented in the percentage of the vehicle. Two-tailed t-tests were performed. *p < 0.05; Error bars = SEM. Measurements were performed at least as biological triplicates.

Modulation of CaSR and PSEN1 expression at the plasma membrane of fAD neurons treated with calcilytic NPS 2143

To explore whether the effects of calcilytic on AβPP processing observed in PSEN1 mutant cells were due to changes in AβPP—or secretase—expression at plasma membrane, 6-week-old neuronal cultures were treated with NPS 2143 and studied for cell surface proteins localization measured by biotinylation assay. Integrin α7 was used as a positive control for the plasma membrane expression. WB analyses of FT and E samples confirmed that Integrin α7 was exclusively observed in the eluted fractions (Fig. 6A, lanes 2, 4, 6, 8). Based on our results, AβPP and CaSR were expressed at both intracellular and plasma membrane level (Fig. 6A). Moreover, we noted that in control and fAD cells, AβPP expression at the cell surface was not significantly changed following the treatment with calcilytic (Fig. 6A, lane 4 versus lane 2; lane 8 versus lane 6, and Fig. 6B). Interestingly, fAD cells treated with NPS 2143 presented significantly reduced levels of CaSR in the E fraction compared to vehicle treatment (Fig. 6A, lane 8 versus lane 6, and Fig. 6C). In contrast, cell surface expression of CaSR was not affected by calcilytic in the control line (Fig. 6A, lane 4 versus lane 2, and Fig. 6C). In addition, we observed that PSEN1 was mainly expressed intracellularly but it also presented discrete levels at the plasma membrane (Fig. 6A). Similar to what we observed for CaSR, cell surface expression of PSEN1 in fAD cultures incubated with calcilytic was decreased compared to treatment with vehicle (Fig. 6A, lane 8 versus lane 6, and Fig 6D). However, NPS 2143 had no evident effect on PSEN1 plasma membrane presence in control cells (Fig. 6A, lane 4 versus lane 2, and Fig. 6D). Despite the reduction of CaSR and PSEN1 at the cell surface of fAD cells treated with calcilytic, we did not detect evident changes in the levels of these proteins in the corresponding FT fractions (Supplementary Figure 3). Finally, levels of α-secretase ADAM10 and β-secretase BACE1 were assessed. The active form of ADAM10 (∼70 kDa) was mainly present in the E fractions in control cells (Supplementary Figure 4, lanes 1–4), while its expression in the FT and E fractions was similar in fAD neurons (Supplementary Figure 4, lanes 5–8). Instead BACE1 was expressed almost exclusively in the FT fractions of healthy and PSEN1 mutant cells (Supplementary Figure 4). However, cellular localization of ADAM10 and BACE1 was not affected by calcilytic treatment in both cell lines (Supplementary Figure 4).

Fig.6

Modulation of AβPP, CaSR, and PSEN1 at the plasma membrane by NPS 2143 treatment. A) Representative western blot bands representing AβPP, CaSR, and PSEN1 present in the intracellular (flow-through fractions, FT) and in the plasma membrane (Eluate, E) fractions of Ctrl-1 and fAD-1 biotinylated samples treated with vehicle (0.1% DMSO) or with 1 μM NPS 2143 for 48 h. The Integrin α7 is a plasma membrane marker and it has been used as a control of the efficiency of biotinylation; After the E fractions bands of (B) AβPP, (C) CaSR, and (D) PSEN1 were normalized to Integrin α7 (only present in the E fractions), the vehicle treated samples were considered as 100%, while NPS 2143 treated samples were presented in the percentage of the vehicle. Two-tailed t-tests were performed. *p < 0.05; Error bars = SEM. Western blot measurements were performed as biological triplicates.

Based on the results of biotinylation studies, we can conclude that NPS 2143 modulated the presence of CaSR and PSEN1 at the plasma membrane of fAD neuronal cultures only.

DISCUSSION

In this study, we provided evidence for the relevance of iPSC-derived neurons as a suitable in vitro system for studying the cellular mechanisms of AD. Immunocytochemistry and calcium imaging analyses demonstrated expression of neuronal markers together with functional ion channels and neurotransmitter receptors in healthy and fAD iPSC-derived neurons. In agreement with our previous work [16], here we confirmed that iPSC-neurons derived from an early-onset fAD patient presented higher secretion of Aβ₄₂ and higher Aβ₄₂/Aβ₄₀ ratio compared to neurons differentiated from two healthy individuals. Such findings are characteristic of AD phenotype and are in line with results from other groups, which also reported increased amyloid levels and amyloid ratios in iPSC-neurons from patients with mutations in PSEN1 and AβPP genes [13, 14, 22]. Human iPSC-neuronal cultures could represent a more relevant system for modeling complex diseases compared to the widely used cellular models, and it might be a promising tool for developing drug discovery platforms which could improve the translation of preclinical studies to patients. Remarkably, the iPSC technology enables the generation of specialized human cells which retain the genetic background of the individual derived from, thus patient-specific. Such unique characteristic allows to test potential personalized therapeutics while the cell lines derived from healthy individuals provide human-based, tissue-specific cell cultures which may possess more closely physiology to humans than transgenic systems derived cell cultures. Notably, we demonstrated that iPSC neurons from healthy and fAD donors drastically reduced endogenous amyloid secretion in response to treatment with the γ-secretase inhibitor DAPT, an effect also observed in other studies [14, 43]. On the other hand, DAPT induced an intracellular accumulation of AβPP-CTF, as expected [44]. Despite great potential, evidence showed that γ-secretase inhibitors tremendously failed as AD therapeutics so far. This poor outcome is due to several reasons [45]. A most problematic aspect is that γ-secretase is responsible for cleaving several substrates other than AβPP, such as Notch, AβPP-like proteins, and N- and E-cadherins [46], therefore its inhibition impacts other important signaling, producing serious side effects in vivo. In addition, accumulation of AβPP-CTF, consequent to γ-secretase blockage, represents another issue as these AβPP intermediates also become toxic when accumulated [48]. Although usage of γ-secretase inhibitors as AD therapeutics is almost out of further consideration nowadays, these compounds are still largely used as useful research tools for biological investigation. In our case, results mediated by DAPT confirmed that iPSC-neurons have a functional γ-secretase activity and a physiological AβPP processing, which allowed us to test the impact of calcilytic NPS 2143 in these cells.

In order to assess the effects of calcilytic in AD neurons, we first evaluated the presence of CaSR in human neuronal cultures. Interestingly, we demonstrated protein expression of CaSR in human iPSC-derived neurons for the first time. We observed that the receptor is expressed in both control and familial neurons at 6 weeks of differentiation. Although a recent study, which analyzed the receptor expression in transgenic AD mice, reported a higher CaSR expression in the hippocampus of AD animals compared to that of control rodents [49], we did not observe evident differences in receptor protein levels between control and AD neurons at the analyzed time of differentiation. Moreover, CaSR was present in both monomeric and dimeric forms in the iPSC-derived neuronal cultures, with predominance of dimers over monomers, while in the human brain hippocampal sample, only the monomeric form was observed. However, the presence of dimers found in the human derived neurons was also substantiated by comparison with HA-tag-hCaSR-transfected SH-SY5Y cells and human kidney tissue lysate. Considering the lack of studies about CaSR expression in iPSC-neurons to which to refer to, we can only speculate that the difference in CaSR dimeric species observed between derived neuronal cultures and hippocampal tissue could be attributable to the much higher complexity of the brain tissue in terms of kind of cells, which in turn might express different levels and forms of CaSR. Further studies are needed to draw a conclusion.

Importantly, we next reported the beneficial effects of calcilytic in counteracting the pathomechanism of AD. We found that calcilytic reduced levels of Aβ₄₀ and Aβ₄₂ secreted from PSEN1 mutant neurons, while amyloid levels were not affected in the control cell lines. Such NPS 2143-mediated results reported only in fAD neurons would indicate that calcilytic can modulate Aβ levels only in the presence of an AD phenotype. In our fAD model, the increased Aβ₄₂ secretion compared to the healthy counterpart could explain the selective effect of NPS 2143 obtained in these cells. Indeed, according to the hypothesized role of Aβ as an activator of the CaSR [35] and due to the higher presence of Aβ₄₂ in the medium of fAD cells, the receptor of AD cultures might be more activated compared to the receptor of healthy cells, thus justifying the evident effect of NPS 2143 observed only in fAD neurons. In agreement, when NAHAs were treated with NPS 2143 alone, it did not modify the basal levels of the intracellular and the secreted amyloid Aβ₄₂ [34]. Only when cells were exposed to synthetic Aβ, which caused a de novo production and release of amyloid, thus mimicking AD condition, addition of calcilytic was beneficial in counteracting the Aβ-mediated noxious effects [34]. In the indicated study, cells were treated with 20 μM synthetic fAβ_25 - 35, an Aβ₄₂ proxy, to induce an AD phenotype. Indeed, following this treatment, NAHAs displayed an augmented accumulation and secretion of Aβ₄₂ while in parallel, cells presented higher intracellular amounts of Aβ₄₀ and unchanged extracellular Aβ₄₀ levels [34]. The authors found that co-treatment of fAβ_25 - 35 with NPS 2143 fully abolished the Aβ₄₂ intracellular accumulation and release. Instead, co-treatment of fAβ_25 - 35 and calcilytic only partially decreased the Aβ-induced intracellular increase of Aβ₄₀, while it promoted its secretion at the same time [34], which suggested that calcilytic differently modulates the secretion of Aβ₄₀ and Aβ₄₂ from fAβ_25 - 35 exposed astrocytes. In contrast with this report, we found that NPS 2143 induced a similar reduction of both Aβ₄₀ and Aβ₄₂ species in the medium of our fAD cellular system. Considering that NPS 2143 modified the endogenously secreted amyloid levels of iPSC-derived neurons without any exogenous amyloid treatment, the effects exerted by the calcilytic might be physiologically relevant.

In addition, as a new result, we found that PSEN1 mutant patient iPSC-derived neurons endogenously displayed lower levels of sAβPPα in the conditioned media compared to control cells. This observation represents a remarkable feature of AD phenotype which is recapitulated in our in vitro system. Soluble AβPPα is obtained from the α-secretase-mediated cleavage of AβPP, which initiates the non-amyloidogenic pathway of AβPP [50]. Interestingly, evidence reported the loss of sAβPPα during AD [51] and its beneficial role as neurotrophic factor [52], thus modulation of α-cleavage might be an alternative therapeutic approach [53]. Similar to what was observed for amyloid modulation, NPS 2143 was effective in modifying sAβPPα secretion only in fAD cells. Indeed, treatment with calcilytic significantly increased the release of soluble AβPPα from PSEN1 mutant cells, while it did not change the sAβPPα levels secreted from healthy neurons. Overall the amyloid reduction accompanied with the sAβPPα increase observed in PSEN1 mutant neurons treated with NPS 2143 would suggest a role of calcilytic in decreasing the β-amyloidogenic processing of AβPP and promoting the α-non-amyloidogenic pathway, substantiating the hypothesis corroborated by Chiarini and colleagues [37]. Indeed, in addition to the previously mentioned effect of calcilytic in modulating amyloid accumulation and secretion in cortical adult human astrocytes, NAHAs [34], a role for NPS 2143 has been recently reported in modifying the sAβPPα of NAHAs [37]. According to this study, exposure to 20 μM fAβ_25 - 35 induced a reduced secretion while a concomitant intracellular accumulation of endogenous sAβPPα in human adult astrocytes. Interestingly, adding NPS 2143 to fAβ_25 - 35 restored the physiological secretion of sAβPPα from the cells whereas it almost completely abolished its intracellular accumulation. The overall effects of NPS 2143 in reducing Aβ₄₂ levels, and partially Aβ₄₀, and increasing the sAβPPα shedding led authors to hypothesize that calcilytic might favor the non-amyloidogenic AβPP processing versus the amyloidogenic cleavage [37]. Chiarini and coworkers further demonstrated that this “switch” from amyloidogenic to non-amyloidogenic AβPP processing exerted by NPS 2143 was due to the capacity of calcilytic to drive the translocation of AβPP and ADAM10 from intracellular compartment to the plasma membrane in human adult astrocyte cultures. Indeed, the authors found that NPS 2143 increased the expression of AβPP and ADAM10 at cell surface of fAβ_25 - 35 treated astrocytes [37]. In contrast with this evidence, NPS 2143 had no effect in modifying the cellular location of AβPP and ADAM10 in iPSC-derived neurons. However, we demonstrated that calcilytic significantly reduced the expression of CaSR and PSEN1 at the cell surface of fAD neurons, an effect which was not observed in healthy cells. Moreover, the intracellular levels of these proteins were not significantly modified. The calcilytic-mediated reduction of CaSR expression has been reported also by other groups. Huang and Breitweiser reported that allosteric modulators can regulate turnover of the CaSR, modifying the receptor expression levels [54]. Indeed, the authors found that in HEK293 cells transfected with a wild-type FLAG-CaSR, incubation with NPS 2143 for 12 h led to a reduction of CaSR protein expression compared to DMSO-treated cells. Such a decrease was partially rescued when the proteasomal inhibitor MG132 was added to NPS 2143, suggesting that calcilytic destabilizes CaSR and increases endoplasmic reticulum-associated degradation. Further, treatment with calcilytic modified CaSR function, by reducing the CaSR expression at cell surface and the receptor-mediated ERK1/2 phosphorylation [54]. Moreover, Armato and colleagues observed a transient decrease of the total CaSR protein at 24 h in astrocytes treated with NPS 2143 alone, which was rescued at 48 and 72 h. Instead, the receptor levels fell rapidly and were kept steadily reduced between 24 and 72 h in cells co-treated with NPS 2143 and fAβ_25 - 35 [34]. Such effect of NPS 2143 on CaSR expression of human astrocytes, which became strongly evident when calcilytic was added to exogenous Aβ, is in line with the reduction of CaSR observed at the cell surface of fAD-neurons, and it might be connected to the anti-amyloidogenic capacity mediated by NPS 2143 only in the presence of the AD phenotype.

Moreover, the reduction of CaSR at the plasma membrane associated with the decrease of PSEN1 at the cell surface is intriguing and might indicate the probability of a physical interaction between the two proteins. Interestingly, several lines of evidence demonstrated the capability of some GPCRs to physically associate with γ-secretase, modifying its expression and activity. For instance, co-immunoprecipitation assays revealed a physical association of β2-adrenergic receptor (β2AR) with PSEN1 in transfected HEK293 cells [55]. This study reported that agonist of β2AR induced co-internalization of the receptor and PSEN1, which enhanced γ-secretase activity and Aβ production. Conversely, antagonizing of β2AR inhibited Aβ production and reduced cerebral plaques in a transgenic AD mouse model [55]. Similarly, coimmunoprecipitation assays demonstrated the interaction of the δ-opioid receptor (DOR) with PSEN1 and BACE1 which formed a secretases/receptor complex [55, 56]. Activation of DOR mediated the co-endocytic sorting of the GPCR/secretase complex together with an increased activity of secretases and Aβ production. Interestingly, knockdown or antagonization of DOR reduced secretase activities and ameliorated Aβ pathology and Aβ-dependent behavioral deficits, without affecting the processing of Notch, N-cadherin, or APLP, in AD model mice [56]. Although an interaction-based mechanism between CaSR and PSEN1 has not been demonstrated yet, it would represent a possibility to explain the calcilytic-mediated concomitant reduction of these proteins at the cell surface in fAD neurons. Based on our study and on evidence from the literature, we can only speculate that the beneficial effect of calcilytic in ameliorating the AD phenotype of PSEN1 mutant cells is correlated to the CaSR putative heterocomplex with secretases and/or to its internalization and potential degradation mediated by NPS 2143. However, further studies are needed to investigate such complex processes.

Altogether, here we provide evidence that calcilytic positively counteracts amyloid secretion and sAβPPα loss in a relevant model of fAD. It would be interesting to explore whether NPS 2143 produces similar effects in iPSC-neurons derived from individuals with sporadic AD. Indeed, these patients represent the majority of AD cases, totaling about 95% of all patients, whereas only up to 5% are familial cases. Therefore, testing the calcilytic in sporadic iPSC-neurons would be highly relevant and, in the case of a positive outcome, would represent an attractive therapeutic strategy against AD.